



Regulus Therapeutics Inc.
Investor Relations Department
10614 Science Center Dr
San Diego, CA 92121
United States

Visit IR website [↗](#)
Sign-up for Email alerts [↗](#)

NASDAQ: RGLS

Last Trade:	1.21
Trade Time:	4:00 PM ET Oct 20, 2017
Change:	-0.04 ↓ (-3.200%)
Day Range	1.16 - 1.28
52-Week Range	0.79 - 3.38
Volume	455,545


Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Regulus Therapeutics Inc. (Nasdaq: RGLS) is a clinical stage biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced microRNA therapeutics pipeline complemented by a rich intellectual property estate to retain its leadership in the microRNA field. Regulus is advancing several programs in renal, hepatic and central nervous systems diseases. Regulus maintains its corporate headquarters in La Jolla, CA.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- [Aug 30, 2017
Regulus to Present at the 2017 Wells Fargo Healthcare Conference](#)
- [Aug 8, 2017
Regulus to Present at the 2017 Webbush PacGrow Healthcare Conference](#)
- [Aug 1, 2017
Regulus Reports Second Quarter 2017 Financial Results and Recent Events](#)
- [Jul 25, 2017
Regulus Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares](#)
- [Jul 25, 2017
Regulus to Provide Second Quarter 2017 Financial Results on August 1, 2017](#)

Financials [\[View all \]](#)

- [Second Quarter Financial Results](#)
- [Mar 3, 2017
Annual Report \(10-K\)](#)
- [Apr 28, 2017
Proxy Statement \(DEF 14A\)](#)
- [Aug 2, 2017
Quarterly Report \(10-Q\)](#)
- [May 5, 2017
Quarterly Report \(10-Q\)](#)
- [Nov 2, 2016
Quarterly Report \(10-Q\)](#)